Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mayne Pharma Group ( (AU:MYX) ) has issued an update.
Citigroup Global Markets Australia and related Citi entities have notified Mayne Pharma that they have ceased to be substantial shareholders in the company as of 19 March 2026. The change follows a series of adjustments in relevant interests in Mayne Pharma’s ordinary fully paid shares, primarily driven by securities lending arrangements and routine stock market transactions, resulting in Citi’s overall holding falling below the substantial shareholder threshold.
Within the Citi group, Citibank N.A. Sydney Branch and Citigroup Global Markets Australia reduced their relevant interests, while Citigroup Global Markets Limited recorded an increase in its position under securities lending agreements. The reshuffling of holdings adjusts the distribution of Mayne Pharma’s institutional ownership but appears to stem from normal course financing and trading activity rather than a strategic move, with limited immediate operational impact on the drug maker or its broader market positioning.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is a pharmaceutical company listed on the Australian Securities Exchange, focused on developing, manufacturing and marketing branded and generic medicines. The company operates in regulated markets and relies on institutional investors and market intermediaries to provide liquidity and support its capital structure.
YTD Price Performance: -29.26%
Average Trading Volume: 521,501
Technical Sentiment Signal: Sell
Current Market Cap: A$178.7M
See more insights into MYX stock on TipRanks’ Stock Analysis page.